Margaret Liu - Ipsen SA Independent Director
IPN Stock | EUR 111.10 0.50 0.45% |
Director
Dr. Margaret A. Liu, M.D. serves as Independent Director of Ipsen SA June 7, 2017. She is currently a consultant in the fields of health, vaccines and Immunotherapy, for pharmaceutical biotechnology companies, companies institutions, universities, and government scientific research committees. She is Professor at the Karolinska Institute in Stockholm, Sweden since 2003, first as as Visiting Professor, then currently as Foreign Adjunct Professor . She is also Adjunct Full Professor at the University of California at San Francisco since 2013 and President of the International Society for Vaccines since 2016. She previously held various positions in the private and public sectors in parallel with her academic career. From 1984 to 1988, she was Visiting Scientist at Massachussetts Institute of Technology. From 1987 to 1989 she was Instructor of Medicine at Harvard University. From 1989 to 1995, she was Adjunct Assistant Professor of Medicine at the University of Pennsylvania at Philadpelphie. From 1990 at 1997, she was Director, then Senior Director of the Viral and Cell Biology Division at the Laboratories Merck. From 1997 to 2000, she was VicePresident of Research for the Vaccines and VicePresident of the Vaccines and Gene Therapy division of Chiron Corporation in Emeryville, California. From 2000 to 2002, she was Senior Advisor in Vaccinology for the Bill Melinda Gates Foundation. From 2000 to 2006, she was Vice President of the Board of Transgene in Strasbourg, France. From 2005 to 2009, she was Director of Sangamo Biosciences Inc. She is a recognized scientist in the field of research and development in vaccines and vaccination programs against infectious diseases, in particular HIV and in the field of gene therapies. She holds a B.Sc. in Chemistry with honors from Colorado College and a Ph.D. from Harvard Mediccal School. since 2017.
Age | 63 |
Tenure | 8 years |
Phone | 33 1 58 33 50 00 |
Web | https://www.ipsen.com |
Ipsen SA Management Efficiency
The company has return on total asset (ROA) of 0.1026 % which means that it generated a profit of $0.1026 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1944 %, meaning that it generated $0.1944 on every $100 dollars invested by stockholders. Ipsen SA's management efficiency ratios could be used to measure how well Ipsen SA manages its routine affairs as well as how well it operates its assets and liabilities.Management Performance
Ipsen SA Leadership Team
Elected by the shareholders, the Ipsen SA's board of directors comprises two types of representatives: Ipsen SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ipsen. The board's role is to monitor Ipsen SA's management team and ensure that shareholders' interests are well served. Ipsen SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ipsen SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
Marc Garidel, Chairman, CEO and Chairman of Strategic Committee | ||
Paul Sekhri, Independent Director | ||
Henri Beaufour, Director | ||
Gwenan White, Executive Vice President Communications and Public Affairs | ||
Francois Garnier, Executive Vice President General Counsel, Member of the Executive Committee | ||
Carol Xueref, Independent Director | ||
Richard Paulson, Executive Vice President and Chief Executive Officer of Ipsen North America | ||
Dominique Bery, Executive Vice President, Strategy and Transformation | ||
Yan Moore, Senior Vice President Head of Oncology Therapeutics Area | ||
Aidan Murphy, Executive Vice-President Technical Operations | ||
Piet Wigerinck, Independent Director | ||
David Loew, Chief Executive Officer, Director | ||
Margaret Liu, Independent Director | ||
Craig Marks, VicePres Relations | ||
Howard Mayer, Executive Vice President, Head of Research & Development | ||
Yan MD, VP Area | ||
Regis Mulot, Chief Human Resource Officer, Executive Vice President | ||
Alexander McEwan, Vice President and Head of Radiopharmaceuticals | ||
Ivana MagovcevicLiebisch, Executive Vice President Chief Business Officer | ||
Philippe Bonhomme, Director, Permanent representative of Beech Tree SA | ||
Michele Ollier, Independent Director | ||
Carol Stuckley, Independent Director | ||
JeanMarc Parant, Director, representing Employees | ||
Steven Hildemann, Executive Vice President Chief Medical Officer, Head of Global Medical Affairs and Pharmacovigilance | ||
Harout Semerjian, Executive Vice President & President Specialty Care International & Global Franchises | ||
Anne Beaufour, Director, Permanent representative of Highrock S.àr.l. | ||
Philippe LopesFernandes, Executive Vice President Chief Business Officer | ||
Aymeric Chatelier, Interim Chief Executive Officer, Chief Financial Officer, Executive Vice President | ||
Benoit Hennion, Executive Vice President and President Consumer Helathcare | ||
Dominique Laymand, Executive Vice President, Chief Ethics and Compliance Officer | ||
Antoine Flochel, Vice Chairman of the Board | ||
Stephan Gagne, Head Office |
Ipsen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ipsen SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.19 | |||
Return On Asset | 0.1 | |||
Profit Margin | 0.21 % | |||
Operating Margin | 0.28 % | |||
Current Valuation | 8.46 B | |||
Shares Outstanding | 82.63 M | |||
Shares Owned By Insiders | 57.12 % | |||
Shares Owned By Institutions | 20.19 % | |||
Price To Earning | 13.13 X | |||
Price To Book | 2.88 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Ipsen Stock
Ipsen SA financial ratios help investors to determine whether Ipsen Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ipsen with respect to the benefits of owning Ipsen SA security.